Rogers Cody M, Kaur Hardeep, Swift Michelle L, Raina Vivek B, Zhou Shuo, Kawale Ajinkya S, Syed Shahrez, Kelly Korilynn G, Jasper Angela M, Salunkhe Sameer, Kwon Youngho, Wang Jeffrey, Shabestari Aida Badamchi, Daley James M, Sacks Adam, Gaczynska Maria E, Osmulski Pawel A, Rawal Yashpal, Tomimatsu Nozomi, Gayther Simon A, Lawrenson Kate, Burma Sandeep, Wasmuth Elizabeth V, Olsen Shaun K, Zhao Weixing, Hromas Robert, Libich David S, Mazin Alexander V, Zhou Daohong, Greene Eric C, Chowdhury Dipanjan, Sung Patrick
Department of Biochemistry and Structural Biology and Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Science. 2025 May 22;388(6749):881-888. doi: 10.1126/science.adt3034.
Antagonistic activities of the 53BP1 axis and the tumor suppressor BRCA1-BARD1 determine whether DNA double-strand breaks (DSBs) are repaired by end joining or homologous recombination. We show that the CTC1-STN1-TEN1 (CST) complex, a central 53BP1 axis component, suppresses DNA end resection by EXO1 and the BLM-DNA2 helicase-nuclease complex but acts by distinct mechanisms in restricting these entities. Whereas BRCA1-BARD1 alleviates the CST-imposed EXO1 blockade, it has little effect on BLM-DNA2 restriction. CST mutants impaired for DNA binding or BLM-EXO1 interaction exhibit a hyper-resection phenotype and render BRCA1-deficient cells resistant to poly(ADP-ribose) polymerase (PARP) inhibitors. Our findings mechanistically define the crucial role of CST in DNA DSB repair pathway choice and have implications for understanding cancer therapy resistance stemming from dysfunction of the 53BP1 axis.
53BP1轴与肿瘤抑制因子BRCA1 - BARD1的拮抗活性决定了DNA双链断裂(DSB)是通过末端连接还是同源重组进行修复。我们发现,作为53BP1轴核心组分的CTC1 - STN1 - TEN1(CST)复合物可抑制EXO1以及BLM - DNA2解旋酶 - 核酸酶复合物对DNA末端的切除,但在限制这些酶的活性时作用机制不同。虽然BRCA1 - BARD1可缓解CST对EXO1的抑制作用,但对BLM - DNA2的限制作用影响不大。DNA结合或BLM - EXO1相互作用受损的CST突变体表现出过度切除的表型,并使BRCA1缺陷细胞对聚(ADP - 核糖)聚合酶(PARP)抑制剂产生抗性。我们的研究结果从机制上明确了CST在DNA DSB修复途径选择中的关键作用,并对理解源于53BP1轴功能障碍的癌症治疗抗性具有重要意义。